methylcellulose assay, 7 was, respectively, 39.5, 64 and 10 colonies (our normal reference values are 155.37105.0 CFU-GM, 159.4773.2 BFU-E and 38.0723.0 CFU-GEMM from 10 5 plated mononuclear cells), showing impaired in vitro proliferation of committed progenitors as usually observed in MDS.
At last follow up (month 27), the patient is in stable clinical conditions under imatinib at 400 mg/day, with haematological parameters progressively decreasing (Hb 10 g/dl, MCV 113 fl, WBC 3,5 Â 10 9 /l, platelets 85 Â 10 9 /l, reticulocytes 5,620/mmc) and BM persistence of trisomic 8 PhÀ clone in 70% of cells, in the absence of Ph chromosome. LDH is 240 IU/l.
In our case, all performed investigations thus fulfil the criteria for a second haematopoietic disease arisen in a PhÀ clone.
Among all previously reported cases with new PhÀ unrelated clones developed under imatinib, a few of them were also referred as having at least some dysplastic features; however, these cases were mostly interpreted with some reservation, as no development of clinical MDS was unequivocally evidenced and, furthermore, they had all been heavily pretreated which might have induced or favoured the cytogenetic changes. 1, 5, 8 Only in one case, 3 a fatal MDS was clearly associated to the PhÀ clonal evolution during imatinib therapy, administered for a CML relapsed postallograft; in this case, a therapy-related MDS could, however, not be excluded.
By considering possible origin of these abnormal clones, two main hypotheses have been formulated: (1) the new PhÀ clone may represent a preleukaemic stage of CML that might gain a growth advantage under imatinib specifically targeting Ph þ cells, 1 (2) normal or abnormal PhÀ stem cells can be damaged by previous chemotherapy and/or Rx-therapy and thereafter selected for by imatinib. 3 While on previous observations, 1,3,5,9 development of therapy-related MDS could be a reasonable hypothesis, our case was only treated with imatinib; thus the possibility that a genetically instable preleukaemic clone was selected or induced by imatinib treatment does exist. This hypothesis is also supported by the recent observation 6 of the simultaneous occurrence of a t(9;22) (Ph) and a t(2;11) in a patient with CML, and emergence of a new clone with the t(2;11) alone after imatinib therapy, indicating possible selection by therapy of a preleukaemic clone as a first step in the disease development.
The reason for which some cases do not express phenotypic abnormalities while others like ours do, remains to be elucidated. The clinical variability might depend on first instability defect of the preleukaemic PhÀ cells or, alternatively, on the presence of cytogenetically undetectable changes superimposed to trisomy 8 or to other changes occurring in the PhÀ clone. Thus, emergence or expansion of abnormal clones under imatinib therapy should be considered in all patients showing haematological dysplastic features.
Acquisition of cytogenetic abnormalities distinct from the Ph þ clone have rarely been reported also in patients treated with HU or Interferon, suggesting an underlying stem cell defect producing both Ph þ and PhÀ cells. 1, 9 The higher frequency of this phenomenon under imatinib treatment might be related to the superior and more selective control by this drug of the targeted Ph þ clone; different effector mechanisms by the different drugs might also play a role in this event. 10 Moreover, the fact that trisomy 8 is one of the most common secondary changes found in MDS, acute myeloid leukaemias, CML in blast transformation and other haematological malignancies might indicate that its appearance is aspecifically facilitated by cell genetic instability, whereas other aberrations, such as À5 and À7, are more likely induced by exposure to mutagenic events.
Finally, another important issue relates to the treatment policy to be followed in these patients who, while in CCR from CML, develop a second potentially malignant haematological disease, for which other treatment options (drug combinations, intensive therapy and/or BMT?) could be indicated. Several reports have shown that abnormal methylation of CpG islands within gene promoters leads to transcriptional silencing and may contribute significantly to the pathogenesis of human leukemias. Hypermethylation of promoters associated with genes involved in the control of the principal late-G1 cell-cycle checkpoint, the apoptotic program and the cell--cell adhesion is detected with increased frequency in acute lymphoblastic leukemia (ALL). 1 This mechanism provides an alternative route to gene mutation of cancer-related genes.
The normal epithelial cell-specific 1 (NES1) gene (also known as kallikrein 10 gene) resides on chromosome 19q and encodes for a secreted serine protease. The physiological function of NES1 is still not clear. The NES1 gene was identified by virtue of its downregulation in breast cancer cell lines, and is considered to be involved in the regulation of normal cell growth. 2 Further experimental evidence suggests that NES1 may function as a tumor suppressor gene. When the NES1 gene was transfected into the tumorigenic breast cancer line MDA-MB-231, its anchorage-independent growth was reduced, and when this cell line was inoculated into nude mice, tumor formation was significantly decreased.
2 Chromosome 19q13.3-4, the region where the NES1 gene resides, is not prone to mutations, deletions or rearrangement in the majority of human cancers. Furthermore, using a luciferase reporter system, it has been found that most tumor cell lines are able to support full or partial transcription from NES1 promoter, suggesting a role of cis-acting mechanisms of the loss of NES1 expression. Hypermethylation of NES1 gene seems to represent one such mechanism, at least, in breast cancer. 3 Although microsatellite markers from this region have shown that 19q is a common site for loss of heterozygosity in childhood ALL, suggesting the presence of at least one tumor suppressor gene at chromosome 19q, 4 the role of the NES1 gene in leukemia has not been studied to date.
Epigenetic inactivation of NES1 gene was studied in four human precursor-B ALL (BV173, TOM-1, MY and NALM-20)
